MOUNJARO®

MOUNJARO® is a once-weekly injectable prescription medication used to improve blood sugar control in adults with type 2 diabetes. As the first dual GIP and GLP-1 receptor agonist, it enhances insulin secretion, suppresses glucagon release, and slows gastric emptying for comprehensive metabolic support.

Overview

MOUNJARO® (tirzepatide) is an FDA-approved, once-weekly injectable medication for adults with type 2 diabetes mellitus. It is the first and only dual GIP and GLP-1 receptor agonist — a novel mechanism that simultaneously activates two distinct incretin hormone pathways to deliver superior glycemic control. Clinical trials have demonstrated significant improvements in HbA1c reduction alongside meaningful weight loss benefits. The prefilled pen format delivers a precise 12.5 mg/0.5 mL dose, offering convenience and ease of use.

For adults who

Need better blood sugar control in type 2 diabetes mellitus and want a once-weekly treatment option

Want to support

Significant HbA1c reduction, weight loss, and improved overall metabolic health with a single weekly injection

Looking for

An FDA-approved, clinically proven dual-action therapy backed by robust clinical trial data and a major manufacturer

Benefit from

A prefilled pen design that simplifies subcutaneous self-injection with accurate, consistent dosing every time

Administration: Once-weekly subcutaneous injection via prefilled pen. Inject into the abdomen, thigh, or upper arm.

Rotate injection sites each week.

Mechanism & Formulation

GIP Receptor Agonist

Dual Action — Primary Mechanism

MOUNJARO® is the first approved therapy to simultaneously activate glucose-dependent insulinotropic polypeptide (GIP) receptors alongside GLP-1. GIP activation enhances insulin secretion and promotes fat metabolism, contributing to weight loss effects that exceed GLP-1 therapy alone.

GLP-1 Receptor Agonist

Glucose Control & Appetite

By mimicking GLP-1, tirzepatide suppresses glucagon release, slows gastric emptying, and reduces appetite — the well-established pathway for improved postprandial glucose response and sustained blood sugar management in type 2 diabetes.

Prefilled Pen Delivery

12.5 mg / 0.5 mL — Once Weekly

The prefilled autoinjector pen delivers a precise, consistent subcutaneous dose once per week. Injections can be administered in the abdomen, thigh, or upper arm, with site rotation recommended. Manufactured by Eli Lilly and Company to exacting pharmaceutical standards.

All eligibility is reviewed by a licensed medical professional.

Simple. Medical. Personalized.

Medical intake

Answer a few online questions about your health history, lifestyle, and goals — no clinic visits required.

Provider evaluation

A licensed medical professional reviews your intake and determines the safest, most effective option for you.

Personalized plan

Custom treatment plan built around your unique health needs, goals, medical history, and biology.

Ongoing support

Stay connected with your care team for follow-ups, adjustments, and expert answers — all online.

FAQs

Dosage & Administration

MOUNJARO® is administered once weekly via subcutaneous injection using the prefilled autoinjector pen, delivering a precise 12.5 mg/0.5 mL dose. Inject into the abdomen, thigh, or upper arm and rotate injection sites weekly. It may be taken with or without food. If a dose is missed, administer as soon as possible within 4 days. If more than 4 days have passed, skip the missed dose and resume on the next scheduled day. Your provider will determine the appropriate starting dose and escalation schedule based on your individual response and tolerability.

Precautions & Side Effects

MOUNJARO® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should be used with caution in patients with a history of pancreatitis, diabetic retinopathy, renal impairment, or those taking insulin or insulin secretagogues. Serious hypersensitivity reactions have been reported — discontinue immediately if they occur. Not recommended during pregnancy. MOUNJARO® is an FDA-approved medication manufactured by Eli Lilly and Company. For complete prescribing information, consult the official FDA-approved label via DailyMed.

Storage

Store MOUNJARO® prefilled pens refrigerated at 36°F–46°F (2°C–8°C). The pen may be stored at room temperature below 86°F (30°C) for up to 21 days if refrigeration is not available. Do not freeze — discard the pen if it has been frozen. Protect from direct light and heat. Do not use after the expiration date printed on the label. Keep out of reach of children and dispose of used pens safely in an approved sharps container.

The information and products provided on this website are for educational and wellness purposes only and are not intended to diagnose, treat, cure, or prevent any disease. All treatments require evaluation and approval by a licensed healthcare provider through a telemedicine consultation. Individual results may vary, and products carry potential risks and side effects. Certain products may not be evaluated by the U.S. Food and Drug Administration (FDA) unless explicitly stated. Services are provided by licensed physicians and nurse practitioners in states where they are authorized to practice, including California, Florida, Nevada, and other participating states. This service is not intended for medical emergencies. If you are experiencing an emergency, call 911 or seek immediate medical care. We take reasonable measures to protect personal health information in accordance with applicable privacy laws, including HIPAA. By using this website or its services, you agree to our Terms of Service, Privacy Policy, and Telehealth Consent. You must be 18 years of age or older to use this service.